AML-732: Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Ivana Gojo et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 3
POSTER: AML-732 Ziftomenib Combined With Intensive Induction Chemotherapy (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007Amer M. Zeidan, Harry P. Erba, Eunice S. Wang et al.|Clinical Lymphoma Myeloma & Leukemia|2025Cited by 0
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S. Azevedo, N. Pemmaraju, Zohra Nooruddin et al.|Expert Opinion on Biological Therapy|2025Cited by 0
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S. Azevedo, N. Pemmaraju, Zohra Nooruddin et al.|Figshare|2025Cited by 0
The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasmRoberta S. Azevedo, N. Pemmaraju, Zohra Nooruddin et al.|Figshare|2025Cited by 0